<p>隨着美國市場經歷波動期，主要指數因對人工智能泡沫和即將發佈的經濟報告的擔憂而收盤下跌，投資者密切關注科技行業的動態。在這樣的環境下，識別高增長科技股需要尋找基本面強勁且能抵禦市場壓力的公司。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 76 只股票完整列表。</p>
<p>在這裏，我們突出顯示了篩選器中我們首選股票的一個子集。</p>
<h2>Precigen (PGEN)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Precigen, Inc. 是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 13.5 億美元。</p>
<p><strong>運營：</strong> Precigen 專注於利用精準技術開發基因和細胞療法，以應對免疫腫瘤學、自身免疫疾病和傳染病。</p>
<p>儘管目前尚未盈利，Precigen 展現出良好的增長潛力，預計年收入增長 55.8%，遠超美國市場平均水平 10.5%。這一增長得益於生物技術的重大進展，FDA 已批准 PAPZIMEOS™用於治療複發性呼吸道乳頭狀瘤病，這是該領域的首個產品。公司的創新承諾通過相對於其收入的可觀研發投資進一步得以體現，使其在競爭激烈的行業環境中為未來的突破和財務成功奠定了良好基礎。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Precigen 的動態。</li>
<li>通過我們的歷史報告獲取對 Precigen 過去趨勢和表現的洞察。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 PGEN 收入和支出明細</p>
<h2>Roivant Sciences (ROIV)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Roivant Sciences Ltd. 是一家臨牀階段的生物製藥公司，致力於藥物和技術的發現、開發和商業化，市值為 152.3 億美元。</p>
<p><strong>運營：</strong> Roivant Sciences 專注於藥物和技術的發現、開發和商業化，主要通過這些活動產生收入。該公司的市值為 152.3 億美元。</p>
<p>在充滿挑戰的環境中，Roivant Sciences 展現出強大的潛力，預計年收入增長 58.5%，顯著高於美國市場平均水平 10.6%。儘管目前尚未盈利，預計盈利將年增長 46.44%。最近的進展包括 Brepocitinib 在皮肌炎中的積極試驗結果，以及 Mosliciguat 在肺動脈高壓中的二期臨牀試驗，奠定了 2026 年及以後關鍵 FDA 申請和商業發佈的基礎。這些進展突顯了 Roivant 通過創新療法解決關鍵醫療需求的承諾，使其在生物技術行業的未來格局中處於有利位置。</p>
<ul>
<li>點擊這裏通過我們的詳細分析健康報告發現 Roivant Sciences 的細微差別。</li>
<li>通過訪問我們的歷史表現報告評估 Roivant Sciences 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 ROIV 盈利和收入增長</p>
<h2>Semrush Holdings (SEMR)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Semrush Holdings, Inc. 提供在線可見性管理 SaaS 平台，在美國、英國及國際市場運營，市值約為 17.7 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其軟件和編程部門產生收入，該部門帶來了 4.2863 億美元。其運營專注於在各個地區提供全面的在線可見性管理 SaaS 平台。</p>
<p>在行業的一項重大舉措中，Semrush Holdings 最近被 Adobe 以 20 億美元收購，繼續在人工智能和搜索引擎優化的交匯處進行創新。儘管今年淨虧損，Semrush 報告收入強勁增長至 3.2599 億美元，較去年 2.7417 億美元有所上升，突顯其在快速發展的科技環境中的韌性和適應能力。'Semrush One'的推出將傳統 SEO 與人工智能驅動的搜索能力相結合，承諾在包括 ChatGPT 等主要大型語言模型在內的各種平台上增強在線可見性。這一戰略擴展不僅多樣化了 Semrush 的產品，還使其在數字營銷領域中佔據了強有力的位置，因為企業越來越依賴複雜的工具來應對互聯網可見性和品牌參與的複雜性。</p>
<ul>
<li>解鎖我們對 Semrush Holdings 股票分析的全面見解，查看此健康報告。</li>
<li>瞭解 Semrush Holdings 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 SEMR 收入和支出明細</p>
<h2>將想法轉化為行動</h2>
<ul>
<li>點擊這裏訪問我們完整的 76 只美國高增長科技和人工智能股票索引。</li>
<li>對這些企業有投資嗎？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
<h2>尋找新的視角？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>移動基礎設施用於國防和災難</p>
<p>下一波機器人技術不是類人機器人。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>由 CiTech 贊助</p>

PLTR

<p>這篇文章強調了美國市場波動中高增長科技股，重點關注基本面強勁的公司。它列出了像 ADMA Biologics、Marker Therapeutics 和 Palantir Technologies 等頂尖公司，並指出了它們的收入和盈利增長。文章還介紹了 Precigen、Roivant Sciences 和 Semrush Holdings，詳細説明了它們的運營和增長潛力。文章強調了創新和戰略擴展在科技行業中的重要性，並通過 Simply Wall St 的分析工具提供了投資機會的見解</p>

<p>As the United States market navigates a period of volatility, with major indexes closing lower amid concerns over an AI bubble and looming economic reports, investors are keenly observing the tech sector's dynamics. In such a climate, identifying high-growth tech stocks involves looking for companies with strong fundamentals and resilience to market pressures.</p>
<div class="lb-trans"><p>隨着美國市場經歷波動期，主要指數因對人工智能泡沫和即將發佈的經濟報告的擔憂而收盤下跌，投資者密切關注科技行業的動態。在這樣的環境下，識別高增長科技股需要尋找基本面強勁且能抵禦市場壓力的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>28.00%</td>
<td>32.57%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Kiniksa Pharmaceuticals International</td>
<td>17.51%</td>
<td>33.44%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Workday</td>
<td>11.15%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>45.93%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 76 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 76 只股票完整列表。</p>
</div><p>Here we highlight a subset of our preferred stocks from the screener.</p>
<div class="lb-trans"><p>在這裏，我們突出顯示了篩選器中我們首選股票的一個子集。</p>
</div><h2>Precigen (PGEN)</h2>
<div class="lb-trans"><h2>Precigen (PGEN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company focused on developing gene and cell therapies for immuno-oncology, autoimmune disorders, and infectious diseases, with a market cap of $1.35 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Precigen, Inc. 是一家發現和臨牀階段的生物製藥公司，專注於開發用於免疫腫瘤學、自身免疫疾病和傳染病的基因和細胞療法，市值為 13.5 億美元。</p>
</div><p><strong>Operations:</strong> Precigen focuses on developing gene and cell therapies using precision technology to address diseases in immuno-oncology, autoimmune disorders, and infectious diseases.</p>
<div class="lb-trans"><p><strong>運營：</strong> Precigen 專注於利用精準技術開發基因和細胞療法，以應對免疫腫瘤學、自身免疫疾病和傳染病。</p>
</div><p>Despite its current unprofitability, Precigen demonstrates promising growth potential with an expected revenue increase of 55.8% per year, outpacing the US market average of 10.5%. This growth is bolstered by significant advancements in biotechnology, as evidenced by the FDA approval of PAPZIMEOS™ for treating recurrent respiratory papillomatosis—a first in its class. The company's commitment to innovation is further highlighted by a substantial R&amp;D investment relative to its revenue, positioning it well for future breakthroughs and financial success in a competitive industry landscape.</p>
<div class="lb-trans"><p>儘管目前尚未盈利，Precigen 展現出良好的增長潛力，預計年收入增長 55.8%，遠超美國市場平均水平 10.5%。這一增長得益於生物技術的重大進展，FDA 已批准 PAPZIMEOS™用於治療複發性呼吸道乳頭狀瘤病，這是該領域的首個產品。公司的創新承諾通過相對於其收入的可觀研發投資進一步得以體現，使其在競爭激烈的行業環境中為未來的突破和財務成功奠定了良好基礎。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Precigen.</li>
<li>Gain insights into Precigen's past trends and performance with our Past report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Precigen 的動態。</li>
<li>通過我們的歷史報告獲取對 Precigen 過去趨勢和表現的洞察。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0fb7141f-fd80-4e2e-93e9-552be9c67d53/chart/revenue-and-expenses-breakdown"/></p>
<p>PGEN Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PGEN 收入和支出明細</p>
</div><h2>Roivant Sciences (ROIV)</h2>
<div class="lb-trans"><h2>Roivant Sciences (ROIV)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of medicines and technologies, with a market cap of $15.23 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Roivant Sciences Ltd. 是一家臨牀階段的生物製藥公司，致力於藥物和技術的發現、開發和商業化，市值為 152.3 億美元。</p>
</div><p><strong>Operations:</strong> Roivant Sciences focuses on the discovery, development, and commercialization of medicines and technologies, generating revenue primarily from these activities. The company has a market cap of $15.23 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> Roivant Sciences 專注於藥物和技術的發現、開發和商業化，主要通過這些活動產生收入。該公司的市值為 152.3 億美元。</p>
</div><p>Roivant Sciences, amidst a challenging landscape, showcases robust potential with an anticipated 58.5% annual revenue growth, significantly outpacing the U.S. market's average of 10.6%. Despite current unprofitability, earnings are expected to surge by 46.44% annually. Recent strides include positive trial outcomes for Brepocitinib in dermatomyositis and ongoing Phase 2 trials for Mosliciguat in pulmonary hypertension, setting the stage for pivotal FDA filings and commercial launches slated for early 2026 and beyond. These developments underscore Roivant's commitment to addressing critical medical needs through innovative therapies, positioning it favorably within the biotech sector's future landscape.</p>
<div class="lb-trans"><p>在充滿挑戰的環境中，Roivant Sciences 展現出強大的潛力，預計年收入增長 58.5%，顯著高於美國市場平均水平 10.6%。儘管目前尚未盈利，預計盈利將年增長 46.44%。最近的進展包括 Brepocitinib 在皮肌炎中的積極試驗結果，以及 Mosliciguat 在肺動脈高壓中的二期臨牀試驗，奠定了 2026 年及以後關鍵 FDA 申請和商業發佈的基礎。這些進展突顯了 Roivant 通過創新療法解決關鍵醫療需求的承諾，使其在生物技術行業的未來格局中處於有利位置。</p>
</div><ul>
<li>Click here to discover the nuances of Roivant Sciences with our detailed analytical health report.</li>
<li>Evaluate Roivant Sciences' historical performance by accessing our past performance report.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏通過我們的詳細分析健康報告發現 Roivant Sciences 的細微差別。</li>
<li>通過訪問我們的歷史表現報告評估 Roivant Sciences 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/1d84a70b-7896-4d8a-a33c-af4937623fd1/chart/earnings-and-revenue-growth"/></p>
<p>ROIV Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ROIV 盈利和收入增長</p>
</div><h2>Semrush Holdings (SEMR)</h2>
<div class="lb-trans"><h2>Semrush Holdings (SEMR)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Semrush Holdings, Inc. offers an online visibility management SaaS platform operating in the United States, the United Kingdom, and internationally with a market cap of approximately $1.77 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Semrush Holdings, Inc. 提供在線可見性管理 SaaS 平台，在美國、英國及國際市場運營，市值約為 17.7 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its software and programming segment, which brought in $428.63 million. Its operations focus on providing a comprehensive SaaS platform for online visibility management across various regions.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其軟件和編程部門產生收入，該部門帶來了 4.2863 億美元。其運營專注於在各個地區提供全面的在線可見性管理 SaaS 平台。</p>
</div><p>In a significant industry move, Semrush Holdings, recently acquired by Adobe for $2 billion, continues to innovate at the intersection of AI and search engine optimization. Despite a net loss this year, Semrush reported a robust revenue increase to $325.99 million, up from $274.17 million last year, underlining its resilience and adaptability in a rapidly evolving tech landscape. The launch of 'Semrush One' integrates traditional SEO with AI-driven search capabilities, promising enhanced online visibility across various platforms including major LLMs like ChatGPT. This strategic expansion not only diversifies Semrush's offerings but also positions it strongly within the digital marketing sphere as businesses increasingly rely on sophisticated tools to navigate the complexities of internet visibility and brand engagement.</p>
<div class="lb-trans"><p>在行業的一項重大舉措中，Semrush Holdings 最近被 Adobe 以 20 億美元收購，繼續在人工智能和搜索引擎優化的交匯處進行創新。儘管今年淨虧損，Semrush 報告收入強勁增長至 3.2599 億美元，較去年 2.7417 億美元有所上升，突顯其在快速發展的科技環境中的韌性和適應能力。'Semrush One'的推出將傳統 SEO 與人工智能驅動的搜索能力相結合，承諾在包括 ChatGPT 等主要大型語言模型在內的各種平台上增強在線可見性。這一戰略擴展不僅多樣化了 Semrush 的產品，還使其在數字營銷領域中佔據了強有力的位置，因為企業越來越依賴複雜的工具來應對互聯網可見性和品牌參與的複雜性。</p>
</div><ul>
<li>Unlock comprehensive insights into our analysis of Semrush Holdings stock in this health report.</li>
<li>Learn about Semrush Holdings' historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖我們對 Semrush Holdings 股票分析的全面見解，查看此健康報告。</li>
<li>瞭解 Semrush Holdings 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/ea1498cd-82af-446b-851a-9bbea9898ae1/chart/revenue-and-expenses-breakdown"/></p>
<p>SEMR Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 SEMR 收入和支出明細</p>
</div><h2>Turning Ideas Into Actions</h2>
<div class="lb-trans"><h2>將想法轉化為行動</h2>
</div><ul>
<li>Click here to access our complete index of 76 US High Growth Tech and AI Stocks.</li>
<li>Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.</li>
<li>Discover a world of investment opportunities with Simply Wall St's free app and access unparalleled stock analysis across all markets.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們完整的 76 只美國高增長科技和人工智能股票索引。</li>
<li>對這些企業有投資嗎？將您的持股整合到 Simply Wall St 的投資組合中，以獲取通知和詳細的股票報告。</li>
<li>通過 Simply Wall St 的免費應用程序發現投資機會的世界，並獲取各市場無與倫比的股票分析。</li>
</ul>
</div><h2>Searching for a Fresh Perspective?</h2>
<div class="lb-trans"><h2>尋找新的視角？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章來自 Simply Wall St，內容具有一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不旨在提供財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>移動基礎設施用於國防和災難</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>由 CiTech 贊助</p>
</div>

US High Growth Tech Stocks To Watch December 2025

- 美國市場面臨波動，主要指數疲軟，投資者關注科技板塊動態。  
- 前十高增長科技公司包括 ADMA Biologics 和 Marker Therapeutics，分別實現 20.12% 和 75.24% 的收入增長。  
- Precigen 和 Roivant Sciences 等公司具備強勁增長潛力，預計年收入增長超過 58%。

2025 年 12 月值得關注的美國高增長科技股票